Evaxion Unveils AI-Based Hybrid Capsid Polio Designs, EVX-V1 CMV Data
Evaxion and the Gates Foundation developed AI-Immunology™ hybrid capsid and de novo B-cell antigen concepts for next-generation polio vaccines, to be presented at the World Vaccine Congress. It will also reveal EVX-V1 CMV vaccine data combining AI-discovered and optimized antigens, highlighting platform scalability and collaboration potential.
1. AI-Driven Polio Vaccine Design
Evaxion, in collaboration with the Gates Foundation, has applied its AI-Immunology™ platform to generate hybrid capsid constructs and de novo B-cell antigen designs aimed at a next-generation polio vaccine. These concepts seek to combine the immunogenic strengths of existing inactivated and attenuated vaccines to address lingering global transmission risks.
2. EVX-V1 CMV Vaccine Data
At the World Vaccine Congress, Evaxion will reveal preliminary EVX-V1 data, showcasing a multi-component cytomegalovirus vaccine that integrates AI-discovered novel antigens with optimized versions of established CMV targets. Early findings are expected to demonstrate a broader immune response potential compared to current CMV candidates.
3. Strategic Platform Validation
These developments underscore the scalability and versatility of AI-Immunology™, strengthening Evaxion’s position for future collaborations and licensing opportunities. Successful proof-of-concept presentations could accelerate partnerships and support advancement of clinical-stage pipeline programs.